Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD
Key facts
- Phase
- Phase 4
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Trial code
- NCT07859839
- Record updated
- 8 October 2026
- Original description
Absence of a clear standard of care and approved drug for chronic cough, the commonest symptom in ILD, calls for further research in this area. In this study, the investigators aim to compare gabapentin and benzonatate treatment with the standard of care for treating chronic cough in ILD. The investigators hypothesize that both gabapentin and benzonatate will be more effective than standard of care in treating chronic cough in ILD.Read full original descriptionShow less
A Randomized, Open-labelled, Three-Arm Trial of Gabapentin Versus Benzonatate Versus Standard of Care for Chronic Cough in Interstitial Lung Disease
Absence of a clear standard of care and approved drug for chronic cough, the commonest symptom in ILD, calls for further research in this area. In this study, the investigators aim to compare gabapentin and benzonatate treatment with the standard of care for treating chronic cough in ILD. The investigators hypothesize that both gabapentin and benzonatate will be more effective than standard of care in treating chronic cough in ILD.
Inclusion: Established diagnosis of ILD as defined by above; Chronic cough (>= 8 weeks) with NRS ≥ 4/10; On stable treatment for ≥ 8 weeks at screening; No contraindication to Gabapentin or Benzonatate Therapy.
Exclusion: Long term oxygen therapy (LTOT); Acute respiratory infection or ILD exacerbation leading to hospitalization within past 8 weeks of screening; Gastroesophageal reflux disease; Upper airway cough syndrome; Decompensated Heart Failure (New York Heart Association (NYHA) Class III/IV); Chronic liver disease (Child-Pugh class B or C); Known hypersensitivity to Gabapentin or Benzonatate; Co-morbid bronchial asthma or chronic obstructive pulmonary disease (COPD); Renal Impairment (eGFR < 30ml/min/1.73m2); Exposure to Gabapentin/Benzonatate within past 4 weeks; Pregnant or Lactating women.